Office Number: 203-815-5782
CaroGen Corporation is an emerging vaccine immunotherapy company employing a virus-like vesicle (VLV) platform technology developed at Yale University School of Medicine and exclusively licensed for the development and commercialization of vaccine immunotherapies worldwide.
Our vision is to create different, potentially transformative first-in-class nanoparticle therapeutic vaccine immunotherapies designed to engage the body’s immune system to both recognize and fight off infectious diseases and cancer. The company is leveraging the VLV platform and developing a portfolio of vaccine candidates against the following infections/diseases:
The hepatitis B program is CaroGen's lead program and has completed initial proof-of-concept testing in animals which was published in August 2015 in the Journal of Virology. Worldwide, approximately 240 million people live with CHB and 600,000 die each year from HBV-associated liver disease and cancer. The HBV program is undergoing optimization for selection of a clinical candidate capable of stimulating the immune system to multiple HBV target antigens.
Clostridium difficile is a microbial infection that causes severe diarrhea and is a CDC urgent threat due to antimicrobial resistance. It is currently estimated that there are 500,000 infections per year in the US resulting 29,000 deaths/year. There are currently no vaccines for either the prevention or treatment of C. difficile and limited antimicrobial drugs available to treat established infections
Zika is an emerging mosquito-borne virus that has been linked to the the development of microcephaly (abnormal smallness of the head usually associated with mental defects) of babies born form mothers infected with the Zika virus and Guillain-Barré syndrome. As of May 5, 2016, WHO surveillance data / reporting has Zika virus currently circulating in 44 countries with no previous evidence of circulation, and with ongoing transmission by mosquitoes.
SPARK Commercialization Grant Award for C. difficile Vaccine
Farmington, CT - April 18, 2016: CaroGen announced today that University of Connecticut collaborator, Dr. Kamal Khanna, was awarded a SPARK Commercialization Fund grant from the University of Connecticut. The grant is to support the research and development of a VLV-based vaccine against C. difficile infection. The award will support the creation of candidate VLV vaccines and testing their immunogenicity in preclinical models. Click here to read the award notification from SPARK.
CT Backs CaroGen’s Quest to Fight Cancer, Hepatitis B
March 7, 2016: An interview with CaroGen’s President and CEO was published in the Hartford Business Journal where he provides an update on CaroGen’s product development: Click here to read the full interview.
CaroGen Announces Publication of HBV Vaccine Preclinical Research
Hamden CT - August 17, 2015 - CaroGen Corporation, an emerging vaccine company, today announced the electronic publication of a research article entitled “Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection,” which appeared in the August online issue of the Journal of Virology.
CaroGen Fostering Vaccine Development Collaborations with Yale & UConn and Establishing Laboratory
Farmington CT – January 5, 2015 – CaroGen Corporation today announced that it has chosen UConn’s Technology Incubation Program (TIP) in Farmington to establish a laboratory footprint. This expansion will allow CaroGen to more aggressively pursue the advancement of its proprietary virus-like vesicle (VLV) vaccine technology, development of its HBV vaccine program and evaluation of other potential candidate infectious disease vaccines.
CaroGen Receives $500,000 Investment from Connecticut Bioscience Innovation Fund (CBIF)
Hamden CT – December 10, 2014 – CaroGen has been awarded $500,000 from the CBIF to support the continued development of CaroGen's therapeutic Hepatitis B Virus (HBV) vaccine.
CaroGen Wins Entrepreneur Innovation Award from CTNext
Hamden CT – April 3, 2014 – CaroGen was awarded a $10,000 grant by CTNext, a component of Connecticut’s innovation ecosystem to support the success of companies and entrepreneurs, to further support development of its therapeutic vaccine for chronic Hepatitis B (CHB) viral infection.